Cardiovascular Disease Biomarker Discovery: Plasma and Serum Collection Protocols

Cardiovascular diseases remain the leading cause of mortality globally, accounting for approximately 17.9 million deaths annually despite significant therapeutic advances over recent decades. The heterogeneity underlying cardiovascular pathophysiology — encompassing atherosclerosis, heart failure, arrhythmias, valvular disease, and inflammatory cardiac conditions — demands precision medicine approaches tailored to individual patient molecular profiles.¹ Cardiovascular-metabolic conditions are one of the core areas covered by our respiratory & metabolic conditions biospecimen portfolio. Biomarker discovery represents a critical pathway toward this goal, enabling early disease detection, risk stratification, therapeutic monitoring, and mechanistic insight into disease progression. Yet cardiovascular biomarker research confronts substantial pre-analytical challenges, with blood collection, processing, and storage methods profoundly influencing biomarker stability and detectability in downstream assays.

The complexity of cardiovascular disease mechanisms spans multiple biological scales from genetic predisposition through environmental risk factors, systemic inflammation, endothelial dysfunction, thrombotic processes, and myocardial remodeling. Circulating biomarkers reflecting these diverse processes include cardiac-specific proteins released during myocardial injury, inflammatory cytokines indicating systemic inflammation, coagulation factors predicting thrombotic risk, natriuretic peptides signaling hemodynamic stress, and metabolites revealing altered cellular metabolism.² Each biomarker class exhibits unique stability characteristics and collection requirements, with inappropriate handling causing artifactual elevations or depressions masking true biological signals. Standardized specimen collection protocols prove essential for reproducible biomarker measurements enabling cross-study comparisons and clinical translation.

At Sanguine, our cardiovascular biospecimen expertise spans comprehensive specimen menus optimized for diverse biomarker classes. Human Plasma collected in multiple anticoagulant formulations (EDTA, heparin, citrate, ACD) accommodates different analytical platforms and biomarker stability requirements. Human Serum enables clot-activated factor measurements and provides alternative matrices for biomarkers degraded by anticoagulants.³ Human PBMCs and Human Leukopak support cellular phenotyping revealing immune contributions to cardiovascular pathology. Our nationwide collection network across the United States enables flexible protocols accommodating specific biomarker requirements while maintaining rigorous quality standards from study design to receipt of samples.

Plasma Versus Serum Selection for Cardiovascular Biomarkers

The fundamental distinction between plasma and serum — plasma containing all clotting factors maintained through anticoagulation while serum represents the supernatant remaining after clot formation — creates critical implications for biomarker research. Plasma collection preserves physiologic states more closely, capturing circulating factors in their native forms without exposure to clotting cascade activation. However, anticoagulants themselves may interfere with certain assays or bind specific analytes reducing detectability.⁴ Serum collection allows complete clot formation, releasing clot-activated factors and platelet contents potentially valuable for certain biomarkers but introducing pre-analytical variability through variable clotting times and activation states.

Plasma Advantages and Optimal Applications:

• Rapid processing possible (centrifugation immediately after collection)
• Preserves labile coagulation factors (if analyzing hemostasis)
• Higher yield (~15% more volume than serum from same blood draw)
• No clotting time variability affecting biomarker release
• Preferred for most protein biomarkers including troponins, natriuretic peptides, inflammatory cytokines
• Essential for metabolomics preserving small molecule stability
• Required for coagulation studies (fibrinogen, D-dimer, von Willebrand factor)
• Optimal for protease-sensitive biomarkers when protease inhibitors added
• Preferred matrix for most multiplexed cytokine/chemokine panels
• Standard choice for emerging biomarkers lacking established collection protocols

Serum Advantages and Optimal Applications:

• No anticoagulant interference with clinical chemistry assays
• Standard matrix for lipid panels (total cholesterol, HDL, LDL, triglycerides)
• Preferred for cardiac enzyme measurements in some clinical protocols
• Contains clot-activated platelet factors (PDGF, TGF-β, PF4) relevant to certain studies
• Historical clinical reference ranges established in serum
• Simpler collection (no anticoagulant mixing required)
• May show reduced hemolysis versus EDTA plasma in some applications
• Required for specific antibody measurements where anticoagulants interfere

The anticoagulant selection for plasma collection influences biomarker stability, assay compatibility, and cellular contamination risks. EDTA chelates calcium and magnesium, preventing coagulation while stabilizing most protein biomarkers and reducing platelet activation. However, EDTA interferes with assays requiring divalent cations and may affect certain enzyme activities.⁵ Heparin preserves calcium-dependent processes but exhibits batch-to-batch variability, sometimes interferes with PCR if downstream molecular analyses are planned, and may affect certain immunoassays. Citrate provides excellent stability for coagulation factors but dilutes specimens 10% requiring concentration adjustments. Our Human Plasma products are available in all major anticoagulant formulations enabling researchers to select optimal matrices for specific applications.

Emerging Biomarker Classes and Matrix Requirements

Cardiac Troponins:

High-sensitivity cardiac troponin assays detect minute troponin elevations indicating subclinical myocardial injury, enabling early infarction diagnosis and chronic cardiovascular risk assessment. EDTA plasma and lithium heparin plasma both provide acceptable matrices, with minimal troponin degradation when specimens are processed within 4 hours and frozen at -80°C.⁶ Serum shows comparable performance but requires complete clot formation (30-60 minutes) delaying processing. Repeated freeze-thaw cycles degrade troponins significantly, necessitating single-use aliquots for longitudinal studies.

Natriuretic Peptides:

B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) serve as heart failure biomarkers, with plasma levels reflecting hemodynamic stress and ventricular dysfunction. EDTA plasma provides optimal stability, with NT-proBNP remaining stable for 72 hours at room temperature and indefinitely at -80°C. BNP exhibits greater lability, degrading rapidly in serum and requiring prompt processing into EDTA plasma with protease inhibitors.⁷ Our Human Plasma from heart failure patients demonstrates elevated natriuretic peptide levels suitable for assay validation.

Inflammatory Cytokines:

IL-6, TNF-α, IL-1β, and other inflammatory mediators associate with cardiovascular disease progression and adverse outcomes. These cytokines prove highly labile, requiring rapid processing, protease inhibitor addition, and immediate freezing preventing degradation. EDTA or heparin plasma are preferred matrices, with serum showing greater variability due to continued cytokine production during clot formation.⁸ Samples must reach freezers within 60 minutes of collection for optimal preservation. Sanguine’s processing protocols for Human Plasma include optional protease inhibitor cocktails stabilizing labile inflammatory biomarkers.

Metabolites and Lipids:

Cardiovascular metabolism alterations produce circulating metabolite signatures detectable through mass spectrometry-based metabolomics. These small molecules exhibit diverse stability profiles, with some degrading within minutes while others remain stable for days at room temperature. Immediate cold processing into EDTA plasma with rapid freezing at -80°C preserves most metabolite classes.⁹ Lipid measurements require fasting specimens eliminating postprandial triglyceride elevations, with Human Serum providing the established clinical matrix for standard lipid panels.

MicroRNAs:

Circulating microRNAs regulate gene expression and serve as cardiovascular disease biomarkers with remarkable plasma stability. EDTA plasma provides optimal miRNA preservation, with RNase inhibitors optional but recommended for long-term storage exceeding 6 months. Hemolysis catastrophically elevates red blood cell-derived miRNAs, necessitating careful collection technique and hemolysis assessment before analysis.¹⁰ Plasma miRNA levels remain stable through multiple freeze-thaw cycles unlike most protein biomarkers.

Pre-Analytical Variables Impacting Biomarker Measurements

Collection Technique and Processing Timing

Phlebotomy technique influences biomarker profiles through mechanical stress, cellular damage, and platelet activation. Tourniquet application exceeding 2 minutes elevates potassium, lactate dehydrogenase, and proteins through hemoconcentration and stress-induced release.¹¹ Vigorous shaking or foaming during collection causes hemolysis, releasing intracellular contents interfering with numerous assays. Underfilling collection tubes alters blood-to-anticoagulant ratios, potentially insufficient anticoagulation causing microclot formation. Sanguine’s phlebotomy protocols specify standardized tourniquet times, gentle mixing techniques, and tube fill verification preventing common collection artifacts.

Optimal Collection Best Practices:

• Apply tourniquets briefly (<1 minute optimal, <2 minutes maximum)
• Use appropriate needle gauge (21-22G typically) preventing hemolysis
• Fill tubes to manufacturer-specified volumes ensuring proper anticoagulant ratios
• Invert tubes gently (5-10 times) immediately after collection for anticoagulant mixing
• Avoid vigorous shaking or foaming
• Label tubes immediately preventing mix-ups
• Keep specimens at room temperature (not ice) during transport unless protocol specifies otherwise
• Process specimens as quickly as possible minimizing ex vivo changes
• Document exact collection times enabling time-course biomarker studies
• Use consistent fasting states (fasting vs. non-fasting) across research cohorts
• Standardize time-of-day collections when studying biomarkers exhibiting diurnal variation
• Avoid hemolyzed specimens for sensitive biomarkers

Centrifugation parameters substantially impact plasma/serum quality, with insufficient speeds leaving cellular contamination while excessive forces cause hemolysis. Standard protocols specify 1,500-2,000×g for 10-15 minutes at 4°C for plasma separation, though specific biomarkers may require adjusted protocols.¹² Multiple centrifugation steps produce platelet-poor plasma reducing platelet-derived biomarker contributions — beneficial when studying circulating rather than platelet-contained factors. Our Human Plasma undergoes standardized dual-spin processing removing >99% of platelets ensuring minimal cellular contamination.

Storage temperature and duration critically determine biomarker stability, with degradation kinetics varying dramatically across biomarker classes. -80°C storage provides optimal long-term stability for most biomarkers, while -20°C proves insufficient for many labile factors. Freeze-thaw cycles cause progressive protein denaturation and microRNA degradation, necessitating single-use aliquots preventing repeated thawing.¹³ Automated freezers maintaining consistent temperatures without manual defrost cycles prevent temperature excursions degrading stored specimens. Sanguine maintains comprehensive specimen tracking documenting freeze-thaw history enabling quality assessment.

Hemolysis Assessment and Mitigation

Hemolysis — red blood cell rupture releasing intracellular contents into plasma/serum — represents the most common pre-analytical artifact affecting cardiovascular biomarker measurements. Hemoglobin, potassium, lactate dehydrogenase, aspartate aminotransferase, cardiac troponins, and miRNAs artifactually elevate in hemolyzed specimens, potentially confounding disease associations.¹⁴ Visual inspection provides crude hemolysis assessment, with pink or red coloration indicating significant hemolysis. Quantitative methods measuring free hemoglobin or absorbance at 414nm enable objective hemolysis scoring and sample rejection/correction.

Common Hemolysis Causes:

• Small gauge needles (<23G) causing red cell shearing
• Excessive vacuum in collection tubes collapsing veins
• Vigorous shaking or mixing
• Prolonged tourniquet times (>2 minutes)
• Difficult draws requiring multiple needle repositioning
• Alcohol contamination from skin prep entering collection tubes
• Aspirating blood too rapidly through needles
• Processing delays allowing cellular degradation
• Insufficient anticoagulant from tube underfilling
• Freeze-thaw cycles
• Improper storage temperatures

Hemolysis index reporting enables biomarker results correction or sample exclusion if hemolysis exceeds acceptable threshold. Many clinical laboratories automatically measure hemolysis indices, rejecting specimens where interference is likely.¹⁵ Research applications require more stringent hemolysis control since subtle elevations creating clinically insignificant interference may confound biomarker associations in large cohort studies. Sanguine’s quality control protocols include hemolysis assessment on all plasma and serum products, with hemolysis index documentation provided.

Disease-Specific Collection Protocols

Acute Coronary Syndrome Biomarker Studies

Acute coronary syndrome (ACS) biomarker kinetics demonstrate rapid evolution following vessel occlusion, with cardiac troponins rising within 2-4 hours, peaking at 24-48 hours, and remaining elevated for 7-14 days. Serial sampling protocols capture these dynamic profiles, with collections at presentation, 3 hours, 6 hours, 12 hours, 24 hours, and 48 hours documenting troponin trajectories distinguishing myocardial infarction from other chest pain etiologies.¹⁶ Our Human Plasma from ACS patients collected at multiple timepoints enables assay development and validation studies requiring serial specimens.

ACS Serial Collection Protocol:

• Emergency department presentation (baseline)
• 3 hours post-presentation (early rise detection)
• 6 hours (standard diagnostic timepoint)
• 12 hours (peak or near-peak levels)
• 24 hours (definitive diagnosis, risk stratification)
• 48-72 hours (peak for late presenters)
• Pre-discharge (prognostic assessment)
• 30-day follow-up Human Serum (outcomes correlation)

Heart Failure Biomarker Research

Chronic heart failure demonstrates persistent biomarker elevations with dynamic changes during decompensation episodes. Natriuretic peptide levels correlate with symptom severity, hemodynamic stress, and prognosis, enabling therapeutic monitoring through serial measurements.¹⁷ Collection protocols require standardized clinical states (resting, fasting) since BNP/NT-proBNP exhibit postprandial elevation and diurnal variation. Comprehensive protocols collect Human Plasma at diagnosis, during dose optimization, at stable chronic state, during acute decompensation, and post-stabilization tracking treatment responses.

Heart Failure Longitudinal Protocol:

• New diagnosis baseline (comprehensive biomarker panel)
• Monthly during initial treatment optimization
• Quarterly during stable chronic phase
• Hospitalization for decompensation (admission + daily + discharge)
• 30-day post-discharge (readmission risk assessment)
• Annual comprehensive reassessment

Atherosclerosis Progression Studies

Subclinical atherosclerosis progresses slowly over years before manifesting as clinical events, with inflammatory biomarkers, oxidized LDL, and endothelial dysfunction markers correlating with plaque burden and progression rates. Longitudinal studies tracking biomarker changes require annual or biannual Human Plasma and Human Serum collections paired with imaging assessments quantifying plaque volume and composition.¹⁸ Population studies enrolling thousands of initially healthy individuals enable identifying biomarkers predicting incident cardiovascular events decades before clinical manifestation.

Cellular Biomarkers and Immunophenotyping

Cardiovascular disease pathogenesis involves complex immune responses, with circulating immune cell phenotypes serving as disease biomarkers and mechanistic indicators. Monocyte subsets (classical CD14++CD16-, intermediate CD14++CD16+, non-classical CD14+CD16++) distribute differently in cardiovascular disease patients versus healthy controls, with pro-inflammatory non-classical monocytes associating with adverse outcomes.¹⁹ Flow cytometric immunophenotyping of Human PBMCs quantifies these populations, requiring careful processing maintaining cellular integrity and preventing ex vivo activation.

Key Immune Populations in Cardiovascular Disease:

• Monocyte subsets (differential functions in inflammation and healing)
• T cell subsets (CD4+ helper, CD8+ cytotoxic, regulatory T cells)
• B cells and antibody profiles (autoimmune contributions to atherosclerosis)
• Natural killer cells (potential protective roles)
• Neutrophils and neutrophil extracellular traps (thrombotic mechanisms)
• Circulating endothelial progenitor cells (vascular repair capacity)
• Platelet-leukocyte aggregates (inflammatory signaling)

Specialized collection tubes preserve RNA and protein expression for transcriptomic and proteomic studies. PAXgene tubes stabilize RNA within minutes of collection, enabling gene expression profiling revealing cellular activation states and inflammatory signatures. However, these tubes are incompatible with flow cytometry, requiring separate Human Whole Blood collection in EDTA tubes when both molecular and cellular analyses are planned.²⁰ Sanguine coordinates multi-tube collections ensuring all required matrices are available from single venipuncture events minimizing patient burden.

Specialized Cardiovascular Biospecimen Types

Circulating Endothelial Cells and Microparticles

Circulating endothelial cells (CECs) sloughed from damaged vessel walls and endothelial microparticles (EMPs) released during cellular activation serve as cardiovascular injury biomarkers. These rare populations require specialized collection and processing, with immediate processing essential since EMPs continue shedding ex vivo.²¹ Flow cytometry enumeration uses endothelial markers (CD31, CD146, CD105), with elevated levels indicating acute vascular injury. Human Whole Blood collected in citrate tubes and processed within 4 hours provides optimal CEC/EMP recovery.

Platelet Function Biomarkers

Platelet activation and aggregation contribute critically to thrombotic cardiovascular events, with ex vivo platelet function testing predicting bleeding and thrombotic risks. However, platelets activate rapidly during blood collection and processing, requiring meticulous technique preventing artifactual activation. Citrate anticoagulation preserves platelet function better than EDTA, with immediate processing and temperature control preventing progressive activation.²² Human Plasma collected under citrate anticoagulation enables aggregometry and other platelet functional assays when processed from citrated whole blood within 2 hours of collection.

Extracellular Vesicles and Exosomes

Extracellular vesicles (EVs) including exosomes released from cardiomyocytes, endothelial cells, and immune cells carry RNA, proteins, and lipids between cells, serving as intercellular communication vehicles and biomarker sources. EV isolation from plasma requires careful processing preventing cellular contamination contributing EVs during processing rather than reflecting circulating populations.²³ Sequential centrifugation removes cells and platelets before ultracentrifugation pellets EVs. Standardized collection protocols specify anticoagulant types, processing timing, and centrifugation parameters affecting EV yields and characterization.

Multi-Omic Integration for Cardiovascular Biomarker Discovery

Modern cardiovascular biomarker discovery increasingly employs multi-omic approaches integrating genomics, transcriptomics, proteomics, metabolomics, and lipidomics to comprehensively characterize disease states. These approaches generate vast molecular profiles from single specimens, revealing systemic perturbations invisible to single-biomarker studies.²⁴ However, multi-omic studies demand careful specimen collection and processing since different analytical platforms exhibit varying sensitivity to pre-analytical variables.

Optimal Specimen Allocation for Multi-Omic Studies:

• Genomics: Human Whole Blood (10 mL) for germline DNA extraction
• Transcriptomics: PAXgene tubes preserving RNA or Human PBMCs processed <4 hours
• Proteomics: Human Plasma (5-10 mL) with protease inhibitors, depleted or undepleted
• Metabolomics: Human Plasma (2-5 mL) rapidly processed and frozen
• Lipidomics: Human Plasma or Human Serum (2-5 mL) fasting specimens
• Immune phenotyping: Human PBMCs (20-50 million cells) fresh or cryopreserved
• Single-cell omics: Human Leukopak providing abundant cells (billions)

Machine learning algorithms trained on multi-omic datasets identify biomarker signatures distinguishing disease states, predicting outcomes, and revealing mechanistic insights. These integrated approaches have identified novel cardiovascular disease subtypes with distinct molecular profiles and therapeutic responses, enabling precision medicine implementation.²⁵ However, the computational complexity and specimen requirements necessitate collaborative efforts pooling specimens across institutions — a capability Sanguine supports through customized collection protocols across the United States.

Quality Control and Reference Standards

Biomarker assay standardization requires well-characterized reference materials enabling cross-laboratory comparisons and quality control monitoring. Pooled Human Plasma or Human Serum from healthy donors provides matrix-matched calibrators, though individual biomarker concentrations may not span disease-relevant ranges.²⁶ Commercial reference materials with certified biomarker concentrations enable absolute quantification, though these standards sometimes behave differently than endogenous biomarkers in complex biological matrices.

Essential Quality Control Elements:

• Pooled quality control samples included in every analytical batch
• Control charts tracking assay performance over time
• Coefficient of variation monitoring (intra- and inter-assay)
• Regular recalibration using certified reference materials
• Participation in external quality assessment schemes
• Hemolysis, icterus, and lipemia interference testing
• Matrix effects assessment comparing spiked recovery
• Freeze-thaw stability validation for banked specimens
• Long-term storage stability monitoring at -80°C
• Contamination screening (bacterial, viral if applicable)
• Documentation of all pre-analytical protocols in publications
• Complete reporting of biomarker measurement methods and assay details

Check Our Inventory

Advancing cardiovascular biomarker discovery with premium biospecimens?

Sanguine’s comprehensive specimen menu includes Human Plasma in multiple anticoagulants, Human Serum, Human PBMCs, and Human Leukopak from cardiovascular disease patients and healthy controls, part of our broader respiratory & metabolic conditions biospecimen portfolio. All specimens include comprehensive genomic annotation supporting translational research from study design to receipt of samples.

Request a Custom Quote →

Ethical Sourcing and Regulatory Compliance

All Sanguine biospecimens are collected under IRB-approved protocols with comprehensive informed consent from every donor. Our HIPAA-compliant data management systems protect donor privacy while enabling researchers to access detailed genomic annotation supporting their studies. We maintain ISO 9001:2015 and ISO 13485:2016 certifications demonstrating our commitment to quality management across all operations.

Donor compensation follows ethical guidelines established by professional societies, ensuring voluntary participation without coercion. Geographic diversity in our collection network across the United States supports health equity in research while providing access to underrepresented populations often excluded from biomedical studies. Every specimen is designated Research Use Only (RUO) with clear documentation of its intended application scope.

References

1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints. Clin Pharmacol Ther. 2001;69(3):89-95. doi:10.1067/mcp.2001.113989
3. Simundic AM, Cornes M, Grankvist K, et al. Standardization of collection requirements for fasting samples. Clin Chim Acta. 2014;432:33-37. doi:10.1016/j.cca.2013.11.008
4. Lippi G, Salvagno GL, Montagnana M, et al. Influence of the needle bore size on platelet count and routine coagulation testing. Blood Coagul Fibrinolysis. 2006;17(7):557-561. doi:10.1097/01.mbc.0000245301.31387.ab
5. Hallworth MJ, Epner PL, Ebert C, et al. Current evidence and future perspectives on the effective practice of patient-centered laboratory medicine. Clin Chem. 2015;61(4):589-599. doi:10.1373/clinchem.2014.232629
6. Apple FS, Sandoval Y, Jaffe AS, Ordonez-Llanos J. Cardiac troponin assays: guide to understanding analytical characteristics. Clin Chem. 2017;63(1):73-81. doi:10.1373/clinchem.2016.255109
7. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Preliminary evaluation of the AxSYM B-type natriuretic peptide assay. Clin Chem. 2004;50(7):1104-1106. doi:10.1373/clinchem.2003.030403
8. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements. Curr Opin Clin Nutr Metab Care. 2010;13(5):541-547. doi:10.1097/MCO.0b013e32833cf3bc
9. Breier M, Wahl S, Prehn C, et al. Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. PLoS One. 2014;9(2):e89728. doi:10.1371/journal.pone.0089728
10. Cheng HH, Yi HS, Kim Y, et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One. 2013;8(6):e64795. doi:10.1371/journal.pone.0064795
11. Lima-Oliveira G, Lippi G, Salvagno GL, et al. Processing of diagnostic blood specimens: is it really the first step of the total testing process? Lab Med. 2017;48(2):e21-e26. doi:10.1093/labmed/lmw062
12. Bowen RA, Remaley AT. Interferences from blood collection tube components on clinical chemistry assays. Biochem Med. 2014;24(1):31-44. doi:10.11613/BM.2014.006
13. Mitchell AJ, Gray WD, Hayek SS, et al. Platelets confound the measurement of extracellular miRNA in archived plasma. Sci Rep. 2016;6:32651. doi:10.1038/srep32651
14. Lippi G, Blanckaert N, Bonini P, et al. Haemolysis: an overview of the leading cause of unsuitable specimens. Clin Chem Lab Med. 2008;46(6):764-772. doi:10.1515/CCLM.2008.170
15. Snozek CL, Karon BS, Scott R, et al. Evaluation of the role of hemolysis on assay precision in the clinical setting. Am J Clin Pathol. 2009;131(5):734-739. doi:10.1309/AJCPBVP4UGVVWAGG
16. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. J Am Coll Cardiol. 2018;72(18):2231-2264. doi:10.1016/j.jacc.2018.08.1038
17. Januzzi JL Jr, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure. J Am Coll Cardiol. 2006;47(11):2197-2203. doi:10.1016/j.jacc.2006.03.005
18. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease. JAMA. 2007;298(7):776-785. doi:10.1001/jama.298.7.776
19. Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events. J Am Coll Cardiol. 2012;60(16):1512-1520. doi:10.1016/j.jacc.2012.07.019
20. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem. 2002;48(11):1883-1890.
21. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):27-33. doi:10.1161/ATVBAHA.110.218123
22. Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation. Circulation. 2006;113(25):2888-2896. doi:10.1161/CIRCULATIONAHA.105.596502
23. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018). J Extracell Vesicles. 2018;7(1):1535750. doi:10.1080/20013078.2018.1535750
24. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases. Circulation. 2012;126(9):1110-1120. doi:10.1161/CIRCULATIONAHA.111.060368
25. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations. Curr Probl Cardiol. 2015;40(1):11-41. doi:10.1016/j.cpcardiol.2014.09.003
26. Miller WG, Myers GL, Ashwood ER, et al. State of the art in trueness and interlaboratory harmonization for 10 analytes. Arch Pathol Lab Med. 2008;132(5):838-846. doi:10.5858/2008-132-838-SOTAIT